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Abstract Purpose: Recent in vitro studies suggested that the autocrine leptin loop might contribute to
breast cancer development by enhancing cell growth and survival.To evaluate whether the leptin
system could become a target in breast cancer therapy, we examined the expression of leptin and
its receptor (ObR) in primary and metastatic breast cancer and noncancer mammary epithelium.
Wealso studiedwhether the expressionof leptin/ObRinbreast cancer canbe inducedbyobesity-
related stimuli, such as elevated levels of insulin, insulin-like growth factor-I (IGF-I), estradiol, or
hypoxic conditions.
Experimental Design:The expression of leptin and ObRwas examined by immunohistochem-
istry in148 primary breast cancers and 66 breast cancermetastases aswell as in 90 benignmam-
mary lesions. The effects of insulin, IGF-I, estradiol, and hypoxia on leptin and ObR mRNA
expression were assessed by reverse transcription-PCR in MCF-7 and MDA-MB-231breast
cancer cell lines.
Results: Leptin and ObR were significantly overexpressed in primary and metastatic breast
cancer relative to noncancer tissues. In primary tumors, leptin positively correlated with ObR,
and both biomarkers were most abundant in G3 tumors. The expression of leptin mRNA was
enhanced by insulin and hypoxia in MCF-7 and MDA-MB-231cells, whereas IGF-I and estradiol
stimulated leptinmRNAonly inMCF-7 cells. ObRmRNAwas inducedby insulin, IGF-I, and estra-
diol inMCF-7 cells and by insulin and hypoxia inMDA-MB-231cells.
Conclusions:LeptinandObRare overexpressedinbreast cancer, possibly due tohypoxia and/or
overexposure of cells to insulin, IGF-I, and/or estradiol.
Obesity increases postmenopausal breast cancer risk by 30%
to 50% (1). The exact mechanism of this phenomenon is not
known, but it is assumed that different biologically active
factors that are secreted by adipose tissue, such as estrogens,
insulin, insulin-like growth factor-I (IGF-I), and leptin, might
be implicated (1–5). Although the role of estrogens, insulin,
and IGF-I in breast tumorigenesis has been extensively studied,
the potential role of leptin is just being recognized (2).
The adipokine leptin (obesity protein) acts as a neurohor-
mone-regulating energy balance and food intake in the
hypothalamus. Additionally, leptin has been shown to influ-
ence various processes in peripheral organs (6, 7). In the breast,
leptin is required for normal mammary gland development and
lactation (8), but it might also contribute to mammary
tumorigenesis (2). In support of the latter, there is evidence
that different breast cancer cell lines can express various
isoforms of the leptin receptor (ObR), including the long
signaling form ObRl (9–13). Furthermore, in breast cancer
cells, leptin has been shown to stimulate DNA synthesis and
cell growth acting through multiple signaling cascades, such as
the Janus-activated kinase 2/signal transducers and activators of
transcription 3, extracellular signal-regulated kinase 1/2,
protein kinase Ca, and Akt/GSK3 pathways (9–16). Leptin-
induced cell cycle progression was accompanied by up-
regulation of cyclin-dependent kinase2 and cyclin D1 levels
(15) and hyperphosphorylation/inactivation of the cell cycle
inhibitor pRb (13). Noteworthy, in T47D breast cancer cells,
but not in normal mammary epithelial cells, leptin stimulated
not only cell growth but also cellular transformation (10).
The involvement of leptin in breast carcinogenesis could be
additionally supported by the fact that the hormone can
potentiate estrogen signaling. Specifically, in MCF-7 cells, leptin
induced aromatase gene expression, elevating aromatase
activity and increasing estrogen synthesis (16). Leptin was also
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able to enhance estrogen receptor a (ERa)–dependent tran-
scription by decreasing ERa ubiquitination and degradation,
especially in the presence of the antiestrogen ICI 182,780 (13).
Furthermore, leptin has been shown to transactivate ERa via
the extracellular signal-regulated kinase 1/2 pathway (17).
Limited studies on cancer and noncancer breast biopsies
indicated that both leptin and ObR are present in the human
breast tissue, suggesting that mammary gland can be influenced
by leptin not only through paracrine or endocrine mechanisms
but also by via autocrine pathways (18–21). Importantly, one
previous report (18) and our present study suggest that leptin
and ObR are overexpressed in primary and metastatic invasive
ductal breast carcinoma compared with noncancer mammary
tissue.
The mechanism regulating leptin/ObR overexpression in
mammary epithelium is not known. The synthesis of leptin in
other cellular systems is influenced by different humoral
factors, among them insulin (22, 23), IGF-I, and estrogens
(24). In addition, leptin expression can be up-regulated by
hypoxia via hypoxia-inducible factor 1–mediated transcription
(25, 26). The regulation of ObR is much less understood, but
preliminary evidence suggested that ObR expression can be
stimulated by estradiol and hypoxia in rodents (27). Because
estrogens, insulin, and IGF-I are overabundant in obese subjects
(5), and obesity is associated with tissue hypoxia (28), we
explored whether the expression of the leptin/ObR loop in
breast cancer cells can be affected by these stimuli.
Materials andMethods
Tissue samples
The expression of leptin, ObR, and other breast cancer markers was
assessed in breast cancer and noncancer mammary epithelium. Tissue
samples were obtained from 148 women who underwent partial or
total mastectomy and lymph node dissection for primary breast cancer
as well as from 48 women treated surgically for intraductal proliferative
lesions. Immediately after excision, tissue samples were fixed in 10%
buffered formaldehyde solution, embedded in paraffin blocks at 56jC,
and stained with H&E. Histopathologic examination of sections was
based on the WHO and pTN classification of breast tumors (29). The
protocol of the present study was reviewed and approved by the local
ethical committee.
Breast cancer samples. Breast cancer samples included invasive
ductal carcinomas in grades G2 (57.4%) and G3 (42.6%); in stages pT1
(54.7%) and pT2 (45.3%); 52.7% (78 of 148) of patients had involved
lymph nodes at the time of diagnosis; 66 cases of lymph nodemetastases
were analyzed in parallel with primary tumors. The age of patients with
breast cancer ranged from 30 to 80 years (mean, 54.5 years); 55.4% of
women were premenopausal, and 44.6% were postmenopausal.
Noncancer samples. Ninety cases of intraductal proliferative lesions
were analyzed: 48 cases without accompanying breast cancer (37 usual
ductal hyperplasias and 11 atypical ductal hyperplasias) and 42 cases of
noncancer tissue adjacent to breast cancer. The latter group included 20
cases of usual ductal hyperplasia and 22 cases of atypical ductal
hyperplasia. The age of patients with intraductal proliferative lesions
ranged from 24 to 68 years (mean, 46.8 years); 76.2% of the subjects
were premenopausal, 23.8% postmenopausal.
Immunohistochemistry
The immunohistochemical analysis of leptin, ObR, ERa, ERh, and
Ki-67 expression was carried out using 5-Am consecutive tissue sections
obtained from tissue samples, as described by us previously in detail
(30). The sections were dewaxed in xylene and rehydrated in graded
alcohols. After antigen unmasking and endogenous peroxidase
removal, nonspecific binding was blocked by incubating the slides
for 1 hour with 1.5% normal serum in PBS. Next, the sections were
incubated with the primary antibodies. The following antibodies were
used for immunohistochemistry: for leptin, rabbit polyclonal antibody
A-20 (Santa Cruz Biotechnology, Santa Cruz, CA), dilution 1:100; for
ObR, rabbit polyclonal antibody H-300 (Santa Cruz Biotechnology),
dilution 1:75; for ERa, mouse monoclonal antibody F-10 (Santa Cruz
Biotechnology), dilution 1:200; for ERh, rabbit polyclonal antibody H-
150 recognizing primarily the cytoplasmic form of ERh (Santa Cruz
Biotechnology), dilution 1:200; and for Ki-67, mouse monoclonal
antibody MIB-1 (DAKO, Copenhagen, Denmark Q2), dilution 1:100. The
studies for leptin, ObR, ERa, and ERh were done with avidin-biotin-
peroxidase complex (ABC Staining System, Santa Cruz Biotechnology),
and for Ki-67 with streptavidin-biotin-peroxidase complex (LSAB kit,
DAKO) to reveal antibody-antigen reactions. All slides were counter-
stained with hematoxylin. Breast specimens previously classified as
positive for the expression of the studied markers were used for control
and protocol standardization. In negative controls, primary antibodies
were omitted. The expression of leptin, ObR, ERa, ERh, and Ki-67 was
analyzed by light microscopy in 10 different section fields, and the
mean percentage of tumor cells displaying positive staining was scored.
The expression of leptin and ObR in cancer samples was classified
using a four-point scale: 0, <10% positive cells; 1+, 10 to 50% positive
cells with weak staining; 2+, >50% positive cells with weak staining; 3+,
>50% positive cells with strong staining. The expression of leptin and
ObR in noncancer tissues was classified as negative (<5% of positive
cells) or positive (z5% positive cells). ERa and ERh were classified as
follows: 0, <10% cells with positive staining; 1+, 10% to 50% cells with
positive staining; 2+, 50% to 80% cells with positive staining; 3+ >80%
cells with positive staining. Ki-67 expression was classified as follows: 0,
<10% cells with positive staining; 1+, 10% to 40% cells with positive
staining; 2+ >40% cells with positive staining.
Cell lines
MCF-7 ERa-positive and MDA-MB-231 ERa-negative breast cancer
cell lines were obtained from American Type Culture Collection
(Rockville, MD Q3) and cultured in DMEM:F12 plus 5% calf serum, as
described by us before (31).
Cell treatments
Eighty percent confluent cell cultures were placed in phenol red–free
serum-free DMEM/F12 medium for 24 hours and then treated for 4
hours with 10 nmol/L 17-h-estradiol (E2), 50 ng/mL IGF-I, 100 ng/mL
insulin, or 100 nmol/L CoCl2 (to induce hypoxia). The time and dose
response for all treatments was tested in advance and the conditions
eliciting the maximal leptin and ObR induction were applied.
Reverse transcription-PCR
RNA was isolated from untreated and treated cells using Trizol
(Invitrogen, San Diego, CA Q4). Total RNA (2 Ag) was reverse transcribed
with Superscript2 (Invitrogen). RT product (2 AL) was amplified by PCR
using the following conditions: for leptin, 95jC for 5 minutes, and then
40 cycles of 95jC for 50 seconds, 60jC for 60 seconds, 72jC for 80
seconds, extension 72jC for 10 minutes. Leptin primers: forward, 5V-
CTGTGCCCATCCAAAAAGTCC-3V; reverse, 5V-CCCCCAGGCTGTC-
CAAGGTC-3V(product size 336 bp). Primers for ObR (common domain
ObR and ObRl): 95jC for 5 minutes, and then 30 cycles of 95jC for 40
seconds, 60jC for 50 seconds, 72jC for 50 seconds, 72jC for 10
minutes. Primers for ObR common domain: forward, 5V-CATTTTAT-
CCCCATTGAGAAGTA-3V; reverse, 5V-CTGAAAATTAAGTCCTTGTGC-
CCA-3V(product size 270 bp). Primers for ObRl: forward, 5-CAGAAG-
CCAGAAACGTTTCAG-3V; reverse, 5-AGCCCTTGTTCTTCACCAGT-3V
(product size 344 bp). The expression of a constitutive 36B4 mRNA
was assessed as control of RNA input using primers described before
(32). The PCR products were run on a 2% agarose gel, and the intensity
of bands was quantified by Scion Image laser densitometry program, as
described before (31).
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Statistical analysis
Spearman test was used to analyze correlations among studied
biomarkers in primary breast cancer and in lymph node metastases.
Analyses of correlations were not corrected for multiple comparisons.
The associations of leptin and ObR with clinicopathologic features were
evaluated using m2 and Spearman tests. The significance of reverse
transcription-PCR results was assessed by Student’s t test. Ps < 0.05 were
taken as statistically significant.
Results
Low expression of leptin in benign mammary lesions. The
characteristics of leptin immunostaining in usual and atypical
ductal hyperplasias were similar; therefore, all intraductal
proliferative lesions were treated as one group. Within this
group, positive cytoplasmic leptin immunoreactivity was found
in 15 of 48 (31.3%) of intraductal proliferative lesions without
accompanying breast cancer and in 24 of 42 (57.1%) of benign
mammary lesions adjacent to breast cancer (Table 1T1 ; Fig. 1F1 ).
Enhanced expression of leptin in breast cancer. In primary
breast cancers, leptin was detected in 128 of 148 (86.4%) cases.
Most frequently (64 of 128, 50.0%), leptin immunostaining
was classified as 2+, whereas lower expression (1+) was
observed in 45 of 128 (35.2%) of samples, and high (3+)
expression was found in 19 of 128 (14.8%) of positive tissues
(Table 2T2Q5 ; Fig. 1).
In lymph node metastases, the presence of leptin was noted
in 62 of 66 (93.9%) of cases. Like in primary breast cancer, the
expression of leptin in metastatic cancer was most frequent at
the 2+ level (33 of 62, 53.2% of leptin-positive lymph
node metastases) and less frequent at 3+ (16 of 62, 25.8%)
and 1+ (13 of 62, 20.9%) levels (Table 2; Fig. 1). The expression
of leptin was undetectable in primary and metastatic cancer
samples when immunostaining was done with the omission of
the primary antibody.
Expression of ObR is elevated in breast cancer. The expression
of ObR was examined with the antibody recognizing a
common domain of ObRl and ObRs, allowing for detection
of all ObR isoforms. ObR immunostaining was negative in
almost all studied noncancer tissues (Table 1; Fig. 1). Only in
five specimens of intraductal proliferative lesions, focally
positive cytoplasmic immunostaining for ObR was observed.
In contrast, ObR was often expressed in primary breast
cancers, where cytoplasmic immunoreactivity for ObR was
noted in 61 of 148 (41.2%) of cases. Most frequently (41 of
61, 67.2%), the expression of ObR was weak; however, ObR
staining at 2+ and 3+ levels was also noted in some tissues (15 of
61 and 5 of 61 of positive samples, respectively; Table 2; Fig. 1).
In lymph node metastases, ObR was found in 34 of 66
(51.5%) of specimens. In the majority of positive samples,
the expression of ObR was weak (14 of 34, 41.2%) or medium
(14 of 34, 41.2%). Some metastatic cancers (6 of 34,17.6% of
positive cases) expressed high levels of ObR (Table 2; Fig. 1).
ObR immunoreactivity was undetectable in the control samples
where the primary antibody was omitted.
Leptin and ObR are coexpressed in primary breast cancer. The
expression of leptin in the group of all primary tumors as
well as in the subgroups of ERa-positive and ERa-negative
primary tumors positively correlated with the expression of
ObR (P = 0.002, r = 0.275; P = 0.005, r = 0.393; P = 0.003,
r = 0.411, respectively). In all lymph node metastases as well as
in subgroups derived from ERa-positive or ERa-negative
tumors, the expression of leptin was not significantly associated
with ObR expression (Table 3 T3).
Expression of leptin and ObR is maintained during metastasis
to lymph nodes in ERa-positive tumors. In the group of all
cancer cases, the presence of leptin in primary breast cancer
positively correlated with its expression in matched cases of
lymph node metastases (P = 0.046, r = 0.270; Table 3). After
division of samples into ERa-positive and ERa-negative
subgroups (according to the initial diagnosis of primary
tumor), a strong link between leptin expression in primary
tumor and its metastasis was found only in the subgroup of
ERa-positive tumors (P = 0.008, r = 0.507; Table 3). Similarly,
the expression of ObR in primary tumors positively correlated
with its expression in lymph node metastases only in the
subgroup of ERa-positive tumors (Table 3).
Relationships between the leptin/ObR system and ERa, ERb,
and Ki-67 in primary breast cancers. Because leptin is a mitogen
for breast cancer cells, we assessed the relationship between the
leptin/ObR system and cell proliferation (Ki-67 expression).
Furthermore, because leptin is a modulator of ERa function, we
explored the association between leptin/ObR and ER.
ERa, ERh, and Ki-67 were found in 60.8%, 80.4%, and
64.2% of primary tumors, respectively. In primary tumors,
leptin positively correlated with ERh (P = 0.001, r = 0.327)
but not with ERa or Ki-67 (Table 4 T4). A positive correlation
(P = 0.006, r = 0.378) between leptin and ERh was also found
in the subgroup of ERa-positive but not ERa-negative primary
tumors (Table 4). The expression of ObR in primary tumors
was not significantly associated with the expression of ERa,
ERh, or Ki-67 (Table 4).
Relationships between the leptin/ObR system and ERa, ERb,
and Ki-67 in lymph node metastases. ERa, ERh, and Ki-67
expression were detected in 60.6%, 83.3%, and 68.2% of
Table1. Leptin and ObRexpression levels in non-cancer mammary epithelium
Tissue type Leptin expression ObRexpression
Negative Positive Negative Positive
Noncancer tissuewithout accompanying
breast cancer (n = 48)
33 15 47 1
Noncancer tissue adjacent to breast cancer (n = 42) 18 24 38 4
NOTE: The expression of leptin and ObR was determined in noncancerous mammary tissue, as described in Materials and Methods. The number of cases (n) in each
staining category is shown.
Q1Leptin and ObRin Breast Cancer Progression
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lymph node metastases, respectively. Like in primary tumors,
leptin expression in lymph node metastases was associated with
ERh (P = 0.014, r = 0.338; Table 5T5 ) but not with ERa. This
relationship was also noted in lymph node metastases derived
from ERa-positive (P = 0.029, r = 0.400) but not ERa-negative
primary tumors (Table 5). Interestingly, a negative association
between leptin expression and Ki-67 was found in the subgroup
of metastases derived from ERa-positive but not ERa-negative
primary tumors (Table 5).
The expression of ObR in lymph node metastases positively
correlated with ERa (P < 0.0001, r = 0.442; Table 5) but
not ERh. In addition, ObR negatively correlated with Ki-67
(P = 0.021, r = 0.310; Table 5). These relationships were lost
when we separately analyzed subgroups of lymph node
metastases derived from ERa-positive or ERa-negative primary
tumors (Table 5).
Associations of leptin/ObR with clinicopathologic features. We
studied associations between the leptin/ObR system and lymph
node involvement (pN), tumor size (pT), histologic differen-
tiation (G), menopausal status, and patient age. Notably,
elevated leptin expression was characteristic for less differenti-
ated tumors, specifically high (3+) leptin content positively
correlated with G3 grade (P = 0.031), whereas in tumors with
medium (2+) leptin expression, there was a trend toward a
positive correlation with G3 grade (P = 0.069). On the other
hand, weak (1+) leptin expression was not significantly
associated with tumor differentiation. Similarly, high ObR
expression in primary cancers was more frequent in G3 tumors,
but the association did not reach statistical significance
(P = 0.074). No statistically significant correlations were found
between leptin or ObR and lymph node involvement, tumor
size, menopausal status, and age of patients.
Fig.1. Immunohistochemical detectionof leptin and
ObRexpression.The expression of leptin (A-C)
and ObR (D-F) in noncancer and breast cancer
tissues was studied by immunohistochemistry,
as described in Materials andMethods. In this
representative image, cytoplasmic leptin
immunostaining is seen in intraductal proliferative
lesion (A). In primary breast cancer (B), weak leptin
immunostaining is observed in >50% of cancer
cells (assessed as 2+); strong staining is found in
lymphnode metastasis (C) in >50% of cancer cells
(assessed as 3+). Aweak ObR immunoreactivity
is present in a few epithelial cells in noncancer
mammary gland (D), whereas strong ObR
immunostaining can be seen in primary tumor (E)
and lymphnodemetastasis (F). Original
magnification,200 (A, B, D, and E) and100
(C and F).
Table 2. Leptin and ObR expression levels in primary
andmetastatic breast cancer
Tissue type Leptin expression ObRexpression
0 1+ 2+ 3+ 0 1+ 2+ 3+
PT (n = 148) 20 45 64 19 87 41 15 5
128 61
LNM (n = 66) 4 13 33 16 32 14 14 6
62 34
NOTE: The expression of leptin and ObR was determined in primary breast
cancers and in lymphnodemetastases, as described inMaterials andMethods.
The number of cases (n) in each staining category is shown.
Abbreviations: PT, primary tumors; LNM, lymph nodemetastases.
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Leptin and ObR expression can be induced by different stimuli
in ERa-positive and ERa-negative breast cancer cells. We
studied the possible mechanism of leptin/ObR overexpression
in breast cancer using ERa-positive MCF-7 and ERa-negative
MDA-MB-231 breast cancer cell lines. We focused on factors
and conditions that are known to induce leptin or ObR
expression in other cell systems, especially insulin, IGF-I, E2,
and hypoxia. Insulin, IGF-I and E2 are mitogens for breast
cancer cells, and their levels are often elevated in obese women.
The induction of leptin, ObR (common domain), and ObRl
mRNAs were assessed by reverse transcription-PCR in cells
stimulated with E2, IGF-I, insulin, or CoCl2. In MCF-7 cells, all
stimuli significantly induced leptin mRNA expression, whereas
ObRl and ObR mRNAs were increased by E2, IGF-I and insulin
but not by hypoxia (Fig. 2F2 ).
In MDA-MB-231 cells, leptin and ObR mRNAs, but not ObRl
mRNA, were induced by hypoxia. In addition, insulin
stimulated the expression of leptin, ObR, and ObRl mRNAs.
E2 and IGF-I did not produce significant effects on the leptin/
ObR system (Fig. 2). In both cells lines, the expression of the
control gene 36B4 was not affected by the treatments (Fig. 2).
Discussion
Recent reports suggested that leptin, a hormone whose
expression is elevated in overweight and obese individuals,
might be involved in the development and/or progression of
different cancers. This concept is supported by experimental
evidence that leptin can stimulate cell growth, counteract
apoptosis, and induce migration and expression of matrix
degrading enzymes and angiogenic factors in different cellular
cancer models (2). For instance, in different breast cancer cell
lines, leptin has been shown to stimulate cell proliferation,
survival, and transformation, acting through ObRl, the signal-
ing form of the leptin receptor (2, 10, 11, 13).
The involvement of leptin in mammary carcinogenesis awaits
further validation in animal models and human clinical
material. In this context, new data suggested that leptin is
necessary for mammary tumor development in transforming
growth factor-a transgenic Lep(ob)Lep(ob) mice (33). In
addition, preliminary immunhistochemistry studies described
the expression of ObR and/or leptin in human breast tumors
and normal mammary gland (19). One recent report suggested
that leptin and ObRl are overexpressed in primary breast
tumors relative to normal mammary epithelium (18). No prior
studies were done using clinical samples obtained from
matched pairs of primary breast tumors and lymph node
metastases. Similarly, the regulation of leptin/ObR expression
in breast cancer cells has never been characterized.
Consequently, our goals were (a) to examine the relative
expression of leptin and ObR in primary and metastatic breast
cancer versus noncancer tissue; (b) to evaluate whether the
expression of leptin/ObR system is maintained during metas-
tasis to lymph nodes; (c) to assess the association between
leptin/ObR and other clinicopathologic features, especially
tumor differentiation, expression of ER, and cell proliferation;
(d) to examine whether the expression of the leptin system can
be influenced by obesity-related stimuli, such as high levels of
insulin, IGF-I, estradiol, and hypoxic conditions in ERa-
positive and ERa-negative cells.
We found that leptin and ObR were expressed at low levels in
noncancer tissues, and both markers were overexpressed in
primary breast tumors as well as in lymph node metastases. The
notion that leptin is overexpressed in primary breast tumors is
Table 3. Associations between leptin and ObR in primary tumors and lymphnodemetastases
Compared biomarkers Leptin (PT), ObR (PT),
n = 148, P (r)
Leptin (LNM), ObR (LNM),
n = 66, P (r)
Leptin (PT), leptin (LNM),
n = 66, P (r)
ObR (PT), ObR (LNM),
n = 66, P (r)
All tumors (n = 148) 0.002 (0.275) 0.154 (0.186) 0.046 (0.270) 0.144 (0.191)
ERa+ tumors (n = 90) 0.005 (0.393) 0.120 (0.290) 0.008 (0.507) 0.046 (0.355)
ERa tumors (n = 58) 0.003 (0.411) 0.419 (0.308) 0.449 (0.271) 0.818 (0.055)
NOTE: The associations between the expression of leptin and ObR in primary tumors and lymph node metastases in the group of all tumors and in the subgroups of
ERa-positive and ERa-negative tumors (according to the initial diagnosis of primary tumors) were evaluated by Spearman correlation; P, statistical significance;
r, correlation coefficient; n, number of cases. Statistically significant values are in bold.
Abbreviations: PT, primary tumors; LNM, lymphnodemetastases.
Table 4. Relationships between the leptin system and ERa, ERh, and Ki-67 in primary breast cancers
Compared biomarkers Leptin ERA,
P (r)
Leptin ERB,
P (r)
Leptin Ki-67,
P (r)
ObRERA,
P (r)
ObRERB,
P (r)
ObRKi-67,
P (r)
All PT (n = 148) 0.523 (0.056) 0.001 (0.327) 0.611 (0.056) 0.705 (0.032) 0.353 (0.091) 0.291 (0.103)
ERa+ PT (n = 90) 0.836 (0.024) 0.006 (0.378) 0.289 (0.150) 0.346 (0.102) 0.175 (0.173) 0.263 (0.143)
ERaPT (n = 58)  0.683 (0.092) 0.456 (0.166)  0.451 (0.164) 0.246 (0.252)
NOTE: The associations were evaluated in ERa-positive and ERa-negative primary breast tumors by Spearman correlation; P, statistical significance; r, correlation
coefficient; (), no cases in this category. Statistically significant values are in bold.
Abbreviations: PT, primary tumors; LNM, lymphnodemetastases.
Leptin and ObRin Breast Cancer Progression
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consistent with the results of Ishikawa et al. (18), whereas the
present finding of increased expression of leptin and ObR in
lymph node metastasis versus noncancer breast epithelium is
original. We also report for the first time that in intraductal
proliferative lesions bordering on breast cancer, leptin expres-
sion is higher relative to proliferative lesions without accom-
panying breast cancer, which might imply that leptin abundance
is related to disease progression.
The above results further indicate that breast cancer cells can
be influenced not only by endocrine and/or paracrine leptin
but also via a potent autocrine leptin loop. The function of the
leptin autocrine system might be especially important in
primary tumors where the expression of leptin correlated with
the presence of ObR in both ERa-positive and ERa-negative
tumors. This observation is in agreement with the results of
Ishikawa et al. who found coexpression of leptin and ObRl in
primary ductal breast cancer (18). Here, we additionally
identified a correlation between a less differentiated phenotype
(G3 grade) and the expression of the leptin system in primary
tumors. This notion is consistent with the fact that breast cancer
dedifferentiation can be promoted by hypoxia (34, 35), which
also can induce leptin/ObR expression (see also below).
Notably, the expression of both leptin and ObR in lymph
node metastases was more frequent than their levels in primary
tumors. Whether leptin is truly involved in breast cancer
metastasis is still not known, but a limited analysis of Ishikawa
et al. (18) suggested that the expression of leptin and ObRl is
associated with cancer recurrence in distant organs and a
shorter 5-year disease-free survival. Interestingly, in metastases,
but not in primary tumors, both leptin and ObR negatively
correlated with Ki-67, which could suggest that in metastases
the leptin system is not involved in proliferation.
The mechanisms responsible for leptin/ObR overexpression
in primary and metastatic breast cancer are not clear. Our
results suggest that different stimuli associated with obesity can
induce leptin and ObR mRNA. Most notably, high concen-
trations of insulin and hypoxia stimulated leptin mRNA in both
ERa-positive MCF-7 and ERa-negative MDA-MB 231 cell lines.
Table 5. Relationships between the leptin system and ERa, ERh, and Ki-67 in lymphnodemetastases
Comparedmarkers Leptin ERA,
P (r)
Leptin ERB,
P (r)
Leptin Ki-67,
P (r)
ObRERA,
P (r)
ObRERB,
P (r)
ObRKi-67,
P (r)
All LNM (n = 66) 0.334 (0.124) 0.014 (0.338) 0.016 (0.331) <0.0001 (0.442) 0.092 (0.230) 0.021 (0.310)
LNMderived from ERa+ PT (n = 40) 0.282 (0.172) 0.029 (0.400) 0.031 (0.394) 0.001 (0.507) 0.099 (0.292) 0.388 (0.155)
LNM derived from ERaPT (n = 26) 0.356 (0.207)* 0.433 (0.280) 0.512 (0.236) 0.965 (0.010)* 0.176 (0.494) 0.296 (0.393)
NOTE:The associationswere evaluated in lymphnodemetastases derived fromERa-positive and ERa-negative primary tumors using Spearmancorrelation;P, statistical
significance; r, correlation coefficient. Statistically significant values are in bold.
Abbreviations: PT, primary tumors; LNM, lymph nodemetastases.
*In several cases, ERa-positive metastases originated from ERa-negative primary tumors.
Fig. 2. Effects of E2, IGF-I, insulin, and
hypoxia on leptin and ObRmRNA
expression in breast cancer cells. MCF-7
andMDA-MB-231cells were placed in
serum-freemedium (SFM) for 24 hours and
then stimulated with E2, IGF-I, insulin (Ins),
or CoCl2, as described in Materials and
Methods.The expression of leptin, ObR
(all isoforms), and ObRl (the long form of
the receptor only) mRNAs was probed by
reverse transcription-PCRusing conditions
andprimers listed inMaterials andMethods.
Obtained from at least three independent
experiments.The abundance of leptin, ObR,
and ObRlmRNAs is shown relative to the
levels of 36B4 control mRNA. In all cases,
the relative expression in serum-free
medium is taken as1. Bars, SD. *, statistically
significant differences between treated
and untreated cells.
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ObRl mRNA was induced by hypoxia only in MDA-MB-231
cells. On the other hand, IGF-I and E2 stimulated leptin and
ObR mRNAs in MCF-7 cells. The differential response of MCF-7
and MDA-MB-231 cells to E2 and IGF-I is in agreement with
our previous results (36, 37).
Previous reports suggested a link between leptin and ER.
Leptin has been found to enhance ERa activity and stimulate
the synthesis of estradiol (13, 16, 17). Reciprocally, estradiol
can induce leptin and ObR expression, as shown by this study
and earlier reports in other models (24, 27, 38). It is possible
that ERa effects on leptin/ObR is mediated in part by IGF-I
and insulin systems, as E2 is known to up-regulate both
pathways in breast cancer cells (39–41). Interestingly, in our
study, the expression of leptin and ObR in primary tumors
positively correlated with their presence in matched lymph
node metastases but only in ERa-positive cases, which might
suggests greater stability of the leptin system in this cell
context.
Our study also suggested a relationship between leptin/ObR
and ERh (in particular the cytoplasmatic pool of ERh
recognized by our antibody). The significance of this link is
not clear, especially in light of the controversial role of ERh in
breast cancer (42). However, some reports suggested the
association of ERh with poor prognostic features in breast
cancer (42, 43), which would agree with our and other findings
that the leptin system might be involved in metastasis (2).
In summary, we show that leptin and ObR are overexpressed
in primary breast cancer and lymph node metastasis. This
overexpression could be related to exposure of cells to high
levels of insulin, IGF-I, and estradiol as well as due to hypoxic
conditions. Thus, targeting leptin signaling could be beneficial
for breast cancer therapy and prevention.
Leptin and ObRin Breast Cancer Progression
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